In the country – Bivalent vaccine reduces the risk of ‘serious illness-death’, the main tool to control ‘COVID’

Friday, January 27, 2023, 8:21 a.m.

On January 27, 2023, Assoc. Prof. Dr. Thira Worathanarat, Faculty of Medicine Chulalongkorn University Posted a message regarding the COVID situation on Thira Woratanarat’s Facebook page with the following contents:

January 27, 2023

Yesterday, around the world, there were 147,330 more infections, 744 more deaths, a total of 674,168,661 people, 6,753,161 total deaths.

The top 5 most infected are Japan, South Korea, Taiwan, the United States and Russia.

As of yesterday, in the number of new infections, countries from Europe and Asia occupied seven of the top 10 and 16 of the top 20 globally.

The number of new infections per day around the world right now from Asia and Europe together representing 90.72 percent of the whole world, while the number of deaths accounted for 82.39 percent
…Update US FDA meeting

A key meeting was held last night regarding the VRBPAC committee’s public vaccination plan.

Meeting almost six o’clock in America. or six o’clock in the morning of Thailand today

In essence, the judges voted 21:0 in favor of the bivalent vaccine (containing the original strain along with the BA.4/5 strain) as the main component of vaccines offered to the American public. It will replace the traditional vaccine from the first dose to the booster.

The information presented suggests that Those who received the bivalent vaccine had a 16-fold reduction in the risk of severe illness and a 13-fold reduction in the risk of death compared to the unvaccinated group.

And those who received the bivalent vaccine had a threefold reduction in the risk of severe illness and a twofold reduction in the risk of death compared to those who received the vaccine without the booster dose of the bivalent vaccine.

Another key point that will come up at the meeting is Discussion of future vaccination guidelines how to do There is a draft proposal for consideration according to the news the other day that it will offer once a year injections for people who have received the vaccine before (Figure 1), but it is concluded that VRBPAC has not yet been decided and it is expected that VRBPAC will Let the Advisory Committee on Immunization Practices of the US CDC reconsider.

the above movement This reflects the view that the bivalent vaccine will be the main preventative that will be used in the prevention of COVID-19. And in the future, vaccines will be updated according to the predicted substrains to be suitable for the epidemic strains. As for the long-term booster vaccination, it is unclear. Need to continue to follow each other
…Long COVID update

Landry M and colleagues from George Washington University, USA. Published the research results in the March 2023 edition of the Emerging Infectious Diseases Journal (Figure 2-5).

Study from July 2021 to March 2022 among 1,338 students, faculty members and university personnel infected with COVID-19.

More than a third (36%) of people are experiencing Long COVID.

Long COVID problems are most common among people who are infected with symptoms. and/or have multiple symptoms, people with underlying diseases, women, people who haven’t received all the vaccines, people who smoke or have smoked before

It was also found that complete booster vaccination It will reduce the risk of Long COVID by regarding half. Compared with the group that did not receive the booster vaccine. or groups that have not been vaccinated

…for Thai people

protection once morest infection or re-infection is the best

Wearing a mask correctly and consistently during daily life outside the home It will greatly reduce the risk.

refer

1. Vaccines and Related Biological Products Advisory Committee January 26, 2023 Meeting. US FDA.

2. Live blog: Tracking the meeting of the FDA advisory panel on Covid vaccines. STAT News. 27 January 2023.

3. FDA Advisory Committee Votes to Unify the Strain Composition of COVID-19 Primary and Booster Vaccines. Contagion Live. 27 January 2023.

4. Landry M et al. Postacute Sequelae of SARS-CoV-2 in University Setting. Emerging Infectious Diseases. Volume 29, Number 3—March 2023.

– 006

Leave a Replay